Zhitong Finance App News, Baili Tianheng (688506.SH) issued an announcement. The company recently received the “Drug Clinical Trial Approval Notice” officially approved and issued by the National Drug Administration (NMPA), and the clinical trial of the innovative biopharmaceutical BL-B01D1 (subcutaneous injection) independently developed by the company was approved. It was agreed that this single drug will be clinically tested in patients with advanced solid tumors.

BL-B01D1 for injection (subcutaneous injection) is a subcutaneous preparation developed on the basis of the company Rencan elontuzumab/iza-Bren (BL-B01D1/iza-Bren). It is expected to shorten clinical administration time and improve ease of administration.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.